The Pharmaceutical Industry Has a Question for Space: Where Is the Evidence?

The space industry has become increasingly effective at explaining what microgravity might make possible.

Better protein crystals. New insights into cell behaviour. More sophisticated biological models. Potential advances in pharmaceutical development and manufacturing.

The list is scientifically compelling.

But for the companies responsible for discovering, developing and manufacturing medicines, a more demanding question is emerging.

What would microgravity have to demonstrate before a pharmaceutical company considers it worth investing in?

That question sits at the centre of Microgravity for BioPharma — From Dialogue to Pilot Opportunities, a report published following the inaugural UK–Swiss Microgravity Biopharma Dialogue held at the British Embassy in Berne on 29 June 2026.

The initiative brought together senior representatives from six biopharmaceutical companies, five space companies, academia, government and regulatory organisations.

Its significance lies less in promoting a new scientific frontier than in challenging the assumptions that often accompany emerging technologies.

For microgravity to become relevant to pharmaceutical industry decisions, it must produce evidence that matters to pharmaceutical companies.

And that is a substantially different proposition from demonstrating that an experiment can be performed in orbit.

The dialogue was initiated by Helen Stubbs Pugin of the British Embassy Berne, who developed the subsequent report with Portia Bowman.

The starting observation was revealing.

Discussions about the potential of microgravity for pharmaceuticals frequently involved space technology companies and researchers, but insufficiently represented the pharmaceutical organisations expected to use or finance the resulting capabilities.

The UK–Swiss initiative deliberately changed that conversation.

Rather than beginning with the availability of orbital platforms or technological capabilities, it asked what pharmaceutical companies would need to see before committing scientific expertise, development resources, proprietary data or funding.

Representatives associated with companies including Novartis, Roche, GSK, Johnson & Johnson and Celonic Group contributed pharmaceutical perspectives.

The space sector was represented by specialists from organisations including Frontier Space, BioOrbit, SpacePharma, Spinning Around and Mass Balance.

The result was a discussion grounded in two very different approaches to innovation.

Space technology companies are accustomed to building systems that enable missions and experiments in difficult environments.

Pharmaceutical companies must establish whether scientific observations can support development decisions within demanding research, quality, regulatory and commercial frameworks.

Neither perspective can replace the other.

A viable space-enabled biopharmaceutical programme requires both.

Microgravity can alter physical phenomena involved in sedimentation, buoyancy-driven convection and the behaviour of certain biological and material systems.

These differences provide opportunities to investigate processes under conditions that cannot be reproduced identically in ordinary terrestrial laboratories.

Protein crystallisation is among the best-known research areas.

Scientists have investigated whether microgravity can support crystal growth characteristics that may improve certain structural studies.

Cellular behaviour and tissue models are also attracting attention, particularly where altered mechanical and environmental conditions can help researchers examine biological mechanisms.

But the industrial significance of such observations is application-dependent.

A better crystal does not automatically produce a better medicine.

A different cellular response does not necessarily establish a therapeutic advantage.

And an experiment that works in space may still face considerable obstacles before its findings can influence a commercial pharmaceutical programme.

The essential question is whether microgravity can generate useful information or material properties that justify the additional complexity of accessing, operating within and returning from a space environment.

Without that evidence, the technology remains an interesting research possibility rather than an established industrial tool.

The UK Space Agency's account of the dialogue identified four closely connected requirements: stronger evidence of value, common standards, greater regulatory clarity and wider pharmaceutical-sector understanding.

Together, they describe the practical conditions that would help this emerging market mature.

Pharmaceutical research depends on results that are reproducible, interpretable and relevant to defined development objectives.

For microgravity, this means experiments must be designed around specific scientific questions.

Terrestrial comparison groups, appropriate controls, sample quality, analytical methods and repeatability are essential.

The objective should not merely be to demonstrate a difference between orbital and terrestrial conditions.

It should be to establish whether that difference has meaningful scientific or industrial consequences.

A credible pilot must therefore define what evidence it is intended to produce and how that evidence will be evaluated.

An emerging research field faces difficulties when individual experiments generate information through incompatible procedures or insufficiently documented conditions.

Common approaches to experimental design, data quality, traceability and reporting could make results easier to compare and interpret.

For pharmaceutical companies considering future investment, this matters considerably.

Evidence generated by one organisation becomes more valuable when others can understand how it was produced, identify its limitations and assess its relevance.

Standardisation is not simply an administrative requirement.

It can help create the foundations of a credible industrial evidence base.

The regulatory dimension is particularly significant when space-based research moves towards manufacturing pharmaceutical products.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has been examining how established regulatory principles can apply to medicines manufactured in orbit.

This includes issues related to manufacturing quality, product control, documentation, distribution and oversight.

The UK Space Agency and MHRA have also been working with other public authorities to clarify regulatory pathways for emerging in-orbit manufacturing activities.

This does not mean orbital pharmaceutical products receive automatic regulatory acceptance.

It means regulators are engaging with the practical questions that companies must resolve before developing such products commercially.

For investors and manufacturers, that distinction is critical.

A technology cannot gain meaningful industrial adoption if potential users do not understand its capabilities, limitations and likely costs.

The pharmaceutical sector needs evidence-based explanations rather than broad claims about what space may eventually enable.

Different research applications may benefit from different experimental approaches.

Some may be investigated through terrestrial analogue systems.

Others may require sustained orbital microgravity or access to specialised experimental platforms.

The choice must follow the scientific question.

No single experimental environment should be presented as universally suitable.

The two countries possess capabilities that could contribute to a more mature space-enabled life sciences ecosystem.

The United Kingdom combines an established space sector with commercial companies developing orbital research and manufacturing services.

It also has considerable pharmaceutical research expertise and a regulatory environment actively examining emerging manufacturing models.

Switzerland contributes a globally significant pharmaceutical and biotechnology industry, alongside strong academic research, precision engineering, advanced manufacturing and specialised instrumentation.

These capabilities are complementary.

But their value depends on how effectively they can be integrated into practical research and development programmes.

The UK–Swiss dialogue identified targeted pilot projects, knowledge exchange and consortium-based collaborations as possible routes towards building the evidence needed for broader industry participation.

These approaches offer a more disciplined alternative to investing in experiments without a clearly defined end-user requirement.

Instead of asking companies to purchase access to a novel environment, the challenge becomes identifying a pharmaceutical problem and assembling the capabilities needed to investigate it.

For the Space Systems Innovation Platform (SSIP), the report addresses a challenge closely aligned with its work connecting scientific research, industrial requirements and international space capabilities.

SSIP is an independent Swiss non-profit association headquartered at Technopark Luzern.

Its activities include microgravity-enabled life sciences, advanced manufacturing, orbital infrastructure and the development of structured collaborations between research institutions and industrial organisations.

In July 2026, SSIP announced a strategic partnership with UK-based Frontier Space, intended to connect emerging orbital biotechnology capabilities with the Swiss life sciences and industrial ecosystem.

That collaboration reflects a broader opportunity for organisations working across national and technological boundaries.

A pharmaceutical company may have a defined research question but limited familiarity with the operational requirements of space experimentation.

A research institution may offer specialised biological expertise but require additional hardware development or flight integration support.

A space company may provide access to an orbital environment without being responsible for defining the pharmaceutical relevance of the experiment.

Connecting these capabilities requires more than introductions.

It requires alignment on scientific objectives, responsibilities, experimental requirements, financing, data management and the eventual use of the results.

This is where an independent coordination platform can contribute.

SSIP's potential role is to help structure the collaboration between organisations rather than replace their scientific, commercial or operational responsibilities.

The new report reinforces the importance of beginning that process with industrial demand.

One of the most important implications of the UK–Swiss initiative concerns the scale at which the market should develop.

Large claims about revolutionary medicines manufactured in space may attract attention.

But smaller, carefully designed feasibility programmes may be more useful in establishing whether particular applications deserve further investment.

A well-defined pilot can test a specific scientific hypothesis, compare appropriate experimental conditions and identify practical constraints.

It can also establish whether the results justify a more ambitious experimental programme.

For pharmaceutical companies, this offers a more manageable approach to unfamiliar technology.

For space companies, it provides an opportunity to develop services around clearly identified customer requirements.

For research institutions, it supports investigations with defined questions and transparent success criteria.

And for investors, it can help distinguish emerging evidence from speculative market expectations.

None of this guarantees that microgravity will provide a commercial advantage in every proposed application.

That is precisely why the pilot stage is so important.

Its purpose is to find out.

The publication of the UK–Swiss report comes at a time when commercial space infrastructure, experimental hardware and scientific capabilities are evolving rapidly.

More organisations are considering how orbital environments might contribute to research and industrial development.

But the existence of new infrastructure does not, by itself, create a sustainable market.

Customers must have problems worth solving.

Researchers must establish credible hypotheses.

Engineering providers must deliver reliable systems.

Regulators must be able to assess the relevant processes and products.

And the resulting evidence must justify the resources required.

The discussion is therefore shifting.

The question is becoming less about whether pharmaceutical experiments can be conducted in space and more about which experiments are worth conducting, under what conditions and for what purpose.

For the United Kingdom and Switzerland, the opportunity lies in connecting complementary expertise around those decisions.

For SSIP, it reinforces the importance of industry-led research questions, structured collaborations and technically defensible development pathways.

For the wider space biotechnology sector, the report presents an increasingly important challenge.